RLMD Relmada Therapeutics
- 3.040
- +0.010+0.33%
- 3.040
- 0.0000.00%
Relmada Therapeutics News
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Keybanc rai
Relmada Therapeutics Price Target Cut to $2.00/Share From $3.00 by Goldman Sachs
Relmada Therapeutics Price Target Cut to $2.00/Share From $3.00 by Goldman Sachs
Relmada Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/05/2024 -29.82% Goldman Sachs $3 → $2 Downgrades Neutral → Sell 06/15/2023 812.28% Mizuho → $26 Reitera
Goldman Sachs Downgrades Relmada Therapeutics(RLMD.US) to Sell Rating, Cuts Target Price to $2
Goldman Sachs analyst Andrea Tan downgrades $Relmada Therapeutics(RLMD.US)$ to a sell rating, and adjusts the target price from $8 to $2.According to TipRanks data, the analyst has a success rate of 4
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $25
Mizuho Securities analyst Uy Ear maintains $Relmada Therapeutics(RLMD.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 38.4%
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q1 2024 Earnings Conference
The following is a summary of the Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Call Transcript:Financial Performance:Relmada Therapeutics reported a decrease in total research and development ex
Buy Rating for Relmada Therapeutics Supported by Strong Clinical Pipeline and Financial Stability
Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Express News | Relmada Therapeutics Q1 2024 GAAP EPS $(0.72) Beats $(0.84) Estimate
Relmada Therapeutics | 10-Q: Quarterly report
Press Release: Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PR Newswire CORAL GABLES, Fla., May 8, 2024 CORAL GABLES, Fla., May 8, 2024 /PRNewswire/ -- Relmada T
Express News | Relmada Therapeutics Q1 Cash & Investments USD 83.6 Million
Express News | Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Express News | Relmada Therapeutics Q1 Net Income USD -21.8 Million
Express News | Relmada Therapeutics Q1 EPS USD -0.72
Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...
Analysis
Price Target
No Data
